Skip to contentV
Vaxcyte, Inc.
V
PCVXVaxcyte, Inc. PCVX Q2 2021 · Vaxcyte, Inc. · ThalerReleased Aug 11, 2021, after the close
10-Q filed Aug 11, 2021, 42 days after period end · 0001564590-21-043419
Q2 2021 · 10-Q
Revenue—
Net Income-$23.68M-$23.68MN/M vs Q2 2020N/M vs Q1 2021 EPS Diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR
-$0.46-$0.46N/M vs Q2 2020N/M vs Q1 2021 Operating Income-$23,730,000N/M Operating Cash Flowderived-$28,680,000N/M Free Cash Flowderived-$30,888,000N/M ended Jun 30, 2021 · filed Aug 11, 2021 · 42 d after period end